Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

"Declarations Ethics approval and consent to participateThe study was approved by institutional review boards and independent ethics committees at each center (leading ethics committee: ethics committee at the medical faculty of the University of Aachen) and conducted in accordance with all local legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Patients, Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent at study inclusion. Consent for publicationNot applicable. Competing interestsSteffen Koschmieder reports funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent für BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie.Susanne Isfort reports advisory board honoraria from Pfizer, Incyte, and Novartis,honoraria from Novartis, BMS, Pfizer, Incyte, Abbvie, AOP Orphan and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.Heike Pahl reports advisory board honoraria from Novartis and AOP Pharma. Competing interests Steffen Koschmieder reports funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent für BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie. Susanne Isfort reports advisory board honoraria from Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, Incyte, Abbvie, AOP Orphan and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan. Heike Pahl reports advisory board honoraria from Novartis and AOP Pharma."

"Funding Open Access funding enabled and organized by Projekt DEAL. The JAKoMo trial was funded by Novartis, Germany. As the sponsor of this trial Novartis was involved in the design of the study. Collection, analysis, and interpretation of data and in writing the manuscript were done by investigators in collaboration to Novartis."

"The study was sponsored by Novartis Pharma GmbH (Novartis) and designed by Novartis in collaboration with S. Koschmieder as the medical leading investigator. The study was approved by the institutional review boards of the respective institutions (leading ethics committee: Ethics Committee at the Faculty of Medicine, RWTH Aachen University, Aachen, Germany) before enrollment of patients and was conducted in accordance with the principles of the Declaration of Helsinki. The trial is registered with ClinicalTrials.gov (NCT05044026). Trial registration: NCT05044026; September 14, 2021."